The SAPPHIRE trial (Lancet Neurology, September 2025) tested apitegromab - a myostatin-targeting antibody - atop existing SMA therapy in 240 nonambulatory children and adults. It met its primary endpoint with meaningful motor-function improvement versus placebo, the first phase 3 win for the myostatin-blocking approach in neuromuscular disease.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.